Sign in

CIK 0001818794 · Large accelerated filer

Dyne Therapeutics, Inc.

Sign in to watch
Ticker
DYN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
364883909
Phone
(781) 786-8230
Business address
1560 TRAPELO ROAD, WALTHAM, MA, 02451
  1. 4 Planned sale Director sold 10,952 shares at an average $20.01 ($219,170)
  2. 4 Planned sale Director sold 834,302 shares at an average $19.75 ($16,477,388)
  3. 4 Planned sale Director sold 337,248 shares at an average $20.21 ($6,815,190)
  4. 4 Planned sale Director sold 99,613 shares at an average $20.35 ($2,027,158)
  5. 4 Planned sale Chief Financial Officer sold 5,727 shares at $18.64 ($106,751)
  6. 4 Open-market buy Director bought 2,000 shares at $17.08 ($34,160)
  7. 4 Open-market buy Director bought 2,000 shares at $19.35 ($38,700)
  8. 4 Planned sale Director sold 129,672 shares at $19.52 ($2,530,562)
  9. 4 Planned sale Director sold 688,788 shares at an average $19.09 ($13,149,314)
  10. 4 Open-market buy Director bought 3,000 shares at $15.06 ($45,180)
  11. 4 Planned sale Chief Commercial Officer sold 148 shares at $14.90 ($2,205)
  12. 4 Planned sale Chief Medical Officer sold 904 shares at $14.90 ($13,470)
  13. 4 Planned sale CEO & President sold 2,732 shares at $14.90 ($40,707)
  14. 4 Grant or award CEO & President acquired 180,000 shares (grant or award)
  15. 4 Grant or award Chief Medical Officer acquired 85,000 shares (grant or award)
  16. 4 Grant or award Chief Commercial Officer acquired 60,000 shares (grant or award)
  17. 4 Grant or award Chief Financial Officer acquired 65,000 shares (grant or award)
  18. 4 Derivatives Options or other derivatives
  19. 3 Insider Initial Statement of Ownership
  20. 4 Planned sale CEO & President sold 2,662 shares at $20.72 ($55,157)

Page 3 of 19 · 361 filings